Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio

Once upon a time, beta-blockers (BB) were simply forbidden for the treatment of patients with heart failure (HF): they were thought to worsen clinical severity of the disease, eliciting salt/water retention, reducing myocardial contractility, impairing hemodynamics. [1] Therefore, although the first evidence of metoprolol efficacy was given in 1975, only 20  years after, in 1993, the first randomized study paved the way to a widespread use, finally guideline-recommended since 1999 up to 2021. [2] In the meanwhile, Packer's neurohormonal model of HF overcame the cardiocirculatory and cardiorenal ones.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research